Financials data is unavailable for this security.
View more
Year on year Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd had revenues remain flat at 8.25bn, though the company grew net income 14.49% from 861.79m to 986.71m. A reduction in the cost of goods sold as a percentage of sales from 60.51% to 56.34% was a component in the net income growth despite flat revenues.
| Gross margin | 45.80% |
|---|---|
| Net profit margin | 11.44% |
| Operating margin | 13.11% |
| Return on assets | 8.66% |
|---|---|
| Return on equity | 14.47% |
| Return on investment | 13.55% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd fell by 714.15m. However, the company earned 688.49m from its operations for a Cash Flow Margin of 8.37%. In addition the company used 568.91m on investing activities and also paid 833.77m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.34 |
|---|---|
| Tangible book value per share | 7.85 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.70 |
|---|---|
| Quick ratio | 1.31 |
| Total debt/total equity | 0.2587 |
|---|---|
| Total debt/total capital | 0.2047 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 14.29% and 15.61%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 2.79% |
|---|---|
| Div growth rate (5 year) | 42.22% |
| Payout ratio (TTM) | 105.73% |
| EPS growth(5 years) | 11.94 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -5.95 |
More ▼
